Provided by Tiger Trade Technology Pte. Ltd.

Recursion Pharmaceuticals, Inc.

4.07
-0.0600-1.45%
Post-market: 4.100.0320+0.79%19:58 EDT
Volume:17.48M
Turnover:71.29M
Market Cap:2.18B
PE:-3.98
High:4.17
Open:4.07
Low:3.96
Close:4.13
52wk High:7.18
52wk Low:2.77
Shares:535.00M
Float Shares:522.33M
Volume Ratio:0.90
T/O Rate:3.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0219
EPS(LYR):-1.4410
ROE:-56.58%
ROA:-27.33%
PB:2.38
PE(LYR):-2.82

Loading ...

Nvidia Q2 FY27 Earnings: Gross Margin, Q3 Guidance in Focus

Bellwether Stocks Movement
·
Aug 21

Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says

MT Newswires Live
·
Aug 17

Morgan Stanley Adjusts PT on Recursion Pharmaceuticals to $5.30 From $5.50, Keeps Equalweight Rating

MT Newswires Live
·
Aug 17

Recursion Director Blake Borgeson Disposes of 30,000 Shares for $97,500

Reuters
·
Aug 07

Primer: Recursion Pharmaceuticals (RXRX US) - Aug 2026

Smartkarma
·
Aug 06

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Geron (GERN), Zimmer Biomet Holdings (ZBH) and Recursion Pharmaceuticals (RXRX)

TIPRANKS
·
Aug 06

Recursion Pharmaceuticals, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Recursion Q2 2026 earnings: Expense cuts narrow the net loss

TradingKey
·
Aug 05

Earnings Flash (RXRX) Recursion Pharmaceuticals Posts Q2 Loss $0.25 a Share, vs. FactSet Est of $0.28 Loss

MT Newswires Live
·
Aug 05

Recursion Pharmaceuticals Q2 Operating Revenue USD 7.303 Million Vs. IBES Estimate USD 11.9 Million

Reuters
·
Aug 05

Recursion Pharmaceuticals Q2 Revenue Misses Estimates, Cuts 2026 Expense Outlook

Reuters
·
Aug 05

Recursion Pharmaceuticals Shares Fall 9% Premarket After Q2 Revenue Miss

THOMSON REUTERS
·
Aug 05

Recursion Q2 Net Loss Narrows to $131.01 Million; Revenue Drops to $7.67 Million

Reuters
·
Aug 05

Recursion Pharmaceuticals Q2 EPS $(0.25) Misses $(0.22) Estimate, Sales $7.670M Miss $11.947M Estimate

Benzinga Earnings
·
Aug 05

Recursion Pharmaceuticals Q2 Net Income USD -131.005 Million

THOMSON REUTERS
·
Aug 05

Recursion Pharmaceuticals Inc: Reduced 2026 Cash Operating Expense Guidance to <$375 Mln

THOMSON REUTERS
·
Aug 05

Press Release: Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program

Dow Jones
·
Aug 05

Recursion to Present at Bank of America SMID Cap Executive Insights Event

Reuters
·
Aug 04

Recursion to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Aug 04

Recursion Pharmaceuticals Inc Expected to Post a Loss of 23 Cents a Share - Earnings Preview

Reuters
·
Aug 03